Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review

por Koomen, Bregje M, Badrising, Sushil K, van den Heuvel, Michel M, Willems, Stefan M
Publicado 2020

Barriers and Facilitators for Implementation of a Computerized Clinical Decision Support System in Lung Cancer Multidisciplinary Team Meetings—A Qualitative Assessment

por Klarenbeek, Sosse E., Schuurbiers-Siebers, Olga C. J., van den Heuvel, Michel M., Prokop, Mathias, Tummers, Marcia
Publicado 2020

Impact of time-to-treatment on survival for early-stage non-small cell lung cancer in The Netherlands—a nationwide observational cohort study

por Klarenbeek, Sosse E., Aarts, Mieke J., van den Heuvel, Michel M., Prokop, Mathias, Tummers, Marcia, Schuurbiers-Siebers, Olga C. J.
Publicado 2023

Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care

por Schouten, Robert D., Egberink, Lucie, Muller, Mirte, De Gooijer, Cornedine J., van Werkhoven, Erik, van den Heuvel, Michel M., Baas, Paul
Publicado 2020

Recent Advances and Future Perspective of DC-Based Therapy in NSCLC

por van der Hoorn, Iris A. E., Flórez-Grau, Georgina, van den Heuvel, Michel M., de Vries, I. Jolanda M., Piet, Berber
Publicado 2021

Persistent Exertional Dyspnea and Perceived Exercise Intolerance After Mild COVID-19: A Critical Role for Breathing Dysregulation?

por van Voorthuizen, Esther L, van Helvoort, Hanneke A C, Peters, Jeanette B, van den Heuvel, Michel M, van den Borst, Bram
Publicado 2022

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients

por Koele, Simon E., van Beek, Stijn W., van der Wekken, Anthonie J., Piet, Berber, van den Heuvel, Michel M., ter Heine, Rob
Publicado 2021

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer

por van Delft, Frederik A., Schuurbiers, Milou, Muller, Mirte, Burgers, Sjaak A., van Rossum, Huub H., IJzerman, Maarten J., Koffijberg, Hendrik, van den Heuvel, Michel M.
Publicado 2022

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

por van den Heuvel, Michel M, Verheij, Marcel, Boshuizen, Rogier, Belderbos, José, Dingemans, Anne-Marie C, De Ruysscher, Dirk, Laurent, Julien, Tighe, Robert, Haanen, John, Quaratino, Sonia
Publicado 2015

A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions

por de Rouw, Nikki, Visser, Sabine, Koolen, Stijn L. W., Aerts, Joachim G. J. V., van den Heuvel, Michel M., Derijks, Hieronymus J., Burger, David M., ter Heine, Rob
Publicado 2019

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer

por Otten, Leila S., Piet, Berber, van den Heuvel, Michel M., Marzolini, Catia, van Geel, Robin M.J.M., Gulikers, Judith L., Burger, David M., Leentjens, Jenneke, ter Heine, Rob
Publicado 2022

Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment

por Otten, Leila S., Piet, Berber, van den Haak, Demy, Schouten, Robert D., Schuurbiers, Milou, Badrising, Sushil K., Boerrigter, Emmy, Burgers, Sjaak A., ter Heine, Rob, van den Heuvel, Michel M.
Publicado 2023

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

por de Rouw, Nikki, Boosman, Rene J., Huitema, Alwin D. R., Hilbrands, Luuk B., Svensson, Elin M., Derijks, Hieronymus J., van den Heuvel, Michel M., Burger, David M., ter Heine, Rob
Publicado 2021

The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer

por de Rouw, Nikki, de Boer, Merel, Boosman, René J., van den Heuvel, Michel M., Burger, David M., Lieverse, Joris E., Derijks, Hieronymus J., Frederix, Geert W.J., ter Heine, Rob
Publicado 2022

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden

por van den Heuvel, Guus R. M., Kroeze, Leonie I., Ligtenberg, Marjolijn J. L., Grünberg, Katrien, Jansen, Erik A. M., von Rhein, Daniel, de Voer, Richarda M., van den Heuvel, Michel M.
Publicado 2021

Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy

por van Genugten, Evelien A. J., Weijers, Jetty A. M., Heskamp, Sandra, Kneilling, Manfred, van den Heuvel, Michel M., Piet, Berber, Bussink, Johan, Hendriks, Lizza E. L., Aarntzen, Erik H. J. G.
Publicado 2022

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

por Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
Publicado 2015

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer

por Janssen, Julie M., Verheijen, Remy B., van Duijl, Tirsa T., Lin, Lishi, van den Heuvel, Michel M., Beijnen, Jos H., Steeghs, Neeltje, van den Broek, Daan, Huitema, Alwin D. R., Dorlo, Thomas P. C.
Publicado 2022

Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer

por Schouten, Robert D., Vessies, Daan C. L., Bosch, Linda J. W., Barlo, Nicole P., van Lindert, Anne S. R., Cillessen, Saskia A. G. M., van den Broek, Daan, van den Heuvel, Michel M., Monkhorst, Kim
Publicado 2021

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions

por Hummelink, Karlijn, Muller, Mirte, Linders, Theodora C., van der Noort, Vincent, Nederlof, Petra M., Baas, Paul, Burgers, Sjaak, Smit, Egbert F., Meijer, Gerrit A., van den Heuvel, Michel M., van den Broek, Daan, Monkhorst, Kim
Publicado 2019